Navigation Links
Targeted agent blocked growth of deadly brain cancer in preclinical studies
Date:3/30/2010

Washington, DC A drug already in clinical trials to treat a variety of tumors shows a remarkable ability to shut down growth of glioblastoma in both laboratory cells and in animals, say researchers from Georgetown Lombardi Comprehensive Cancer Center and the University of California, San Francisco (UCSF). In their experiments, the agent put a brake on growth of laboratory cancer cell lines, and no mice with glioblastoma in their brain died as a result of their tumor while on therapy.

They say their findings, reported in the April 15 issue of Cancer Research, provides hope that the drug, PD-0332991, could offer a new treatment option for glioblastoma, which is the most common as well as the deadliest form of brain cancer. A clinical trial testing the therapy in patients with recurrent brain cancer is under development.

"We have had just amazing results in these preclinical studies," says Todd Waldman, MD, PhD, an associate professor of oncology at Lombardi. "We are hopeful it will prove to be effective in brain cancer patients for which there is little effective therapy."

Waldman is the study's co-lead investigator, along with C. David James, PhD, professor of neurological surgery at UCSF. "What is especially encouraging about this agent is that we found it can easily pass through the blood-brain barrier and access glioblastoma, and that there is already a simple test available for screening glioblastoma patients in advance to see whether or not they should be responsive to this therapy," James says.

Given the molecular data from a recently published study by The Cancer Genome Atlas Research Network, about 90 percent of glioblastoma patients have a molecular profile that would make them candidates for the drug, the researchers say.

The drug is currently being tested in clinical trials for otherwise untreatable teratomas, as well as multiple myeloma and breast cancer. It is designed to shut down the activity of molecul
'/>"/>

Contact: Karen Mallet
km463@georgetown.edu
215-514-9751
Georgetown University Medical Center
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Survival in metastatic breast cancer patients is improving: targeted therapies have contributed
2. Gene-Targeted Cancer Fix Could Be a Breakthrough
3. Targeted delivery of losartan reduces liver inflammation and scarring
4. Targeted prevention stopped spread of H1N1 at Alabama boys camp
5. Human Touch Introduces New CirQlation™ Elite Foot & Calf Massager Providing Ultimate Targeted Relief for Tired Feet and Calves
6. Middle Schoolers Identify Violent Content in Youth-Targeted Entertainment as a Strong Influence in Causing Youth Violence
7. Targeted therapy prolongs life in patients with HER2-positive breast cancer
8. Targeted Breast Ultrasound Can Reduce Biopsies for Women Under Forty
9. Targeted breast ultrasound can reduce biopsies for women under 40
10. Targeted Testing Receives Favorable Reviews On PADDS, Begins Nationwide Research Study On The Target Tests of Executive Functioning-OV
11. Reportlinker Adds The Future of Senior Nutrition: Key Ingredients, Strategic Issues and Targeted Opportunities for Older Consumers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... ... August 28, 2015 , ... ... Day at the Zoo to celebrate children helping children, a thank you to ... throughout West Ohio have contributed to the United Methodist initiative to end malaria ...
(Date:8/28/2015)... Angeles, CA (PRWEB) , ... August 28, 2015 , ... ... endless journey that local pizza maker Paul LaRocco has gone through to open a ... city approval and permitting process tends to take several months, but the current process, ...
(Date:8/28/2015)... ... 28, 2015 , ... For Dallas, the time is nearing for the annual ... Tenet Health. , The American Heart Association hosts their well-known Heart Walk to raise ... together, a difference can be made. Walkers can participate in the cause and someone ...
(Date:8/28/2015)... ... 2015 , ... As reported by Medical Daily on August 22 , ... that last for two years, the longest of any cellulite reduction system currently on ... a long-lasting, effective solution for their cellulite, according to Dr. Robert Weiss, director of ...
(Date:8/28/2015)... ... August 28, 2015 , ... On May 30th, 2015, Best Drug Rehabilitation, a ... “Music With A Mission” benefit concert in Mendon, IL. Held in the Show Barn ... to support music education programs in the underfunded local school districts of Mendon at ...
Breaking Medicine News(10 mins):Health News:Saturday’s United Methodist Event at Columbus Zoo Celebrates Imagine No Malaria 2Health News:Saturday’s United Methodist Event at Columbus Zoo Celebrates Imagine No Malaria 3Health News:Article on Building Approval Process for LA Business Highlights the Need for a Bridge Between Businesses and City Officials, says Fire Protection Group Inc. 2Health News:North Central Surgical Center’s Subsidiary Participates in Walk 2Health News:Maryland Dermatologists Discuss Non-Invasive Cellulite Reduction System Cellfina Receiving 2-Year FDA Clearance 2Health News:Maryland Dermatologists Discuss Non-Invasive Cellulite Reduction System Cellfina Receiving 2-Year FDA Clearance 3Health News:New Video Released on "Music With A Mission" Benefit Concert Headlining Artist Cadillac Three & Best Drug Rehabilitation 2
... Beth Israel Deaconess,Medical Center audit, BOSTON, Feb. 6 ... apply the same Sarbanes-Oxley,standards used by Boston Properties and ... of Beth Israel Deaconess Medical Center (BIDMC),according to labor ... the president and CFO of Boston Properties., 1199 ...
... The Female Health Company,(Amex: FHC ) today ... call,to discuss its operating results for the first ... on Wednesday, February 13, 2008. The Company plans,to ... the same day., Shareholders and other interested ...
... asks board member to seek restatement of Beth Israel ... Automation CEO and,director Robert Lepofsky should apply the same ... to his role as Vice,Chairperson of the board of ... (BIDMC), according to labor group 1199 SEIU,United Healthcare Workers ...
... TULSA, Okla., Feb. 6 It takes a team ... That,s the,message of an event scheduled for 10 a.m. ... a significant improvement in Oklahoma,s rates of,early childhood immunizations., ... based on,data from 2005 and 2006, the state improved ...
... Limited, BOSTON, Feb. 6 Patient-Centered Computing,and eHealth: ... will be presented under the auspices of Harvard Medical,School,s ... held,at the Omni Parker House Hotel in Boston, MA ... 2006 event that attracted 120 attendees from,throughout the United ...
... This release is also available in German . ... giant dinosaurs could have lived off more than 100 million years ... to become as large as they did. In actual fact such ... have now been published in the journal ,Proceedings of the Royal ...
Cached Medicine News:Health News:Boston Properties Executive and Board Member Should Use Sarbanes-Oxley Disclosure Rules in Non-Profit Role, Asserts 1199 SEIU 2Health News:The Female Health Company Schedules First Quarter Conference Call for February 13, 2008 2Health News:Brooks Automation Executive and Board Member Should Use Sarbanes-Oxley Disclosure Rules in Non-Profit Role, Asserts 1199 SEIU 2Health News:State Leaders Recognize Oklahoma's Improvement in Immunization Rankings 2Health News:Innovative eHealth Course to Take Place March 28-30 in Boston, Massachusetts 2Health News:Bonn scientists simulate dinosaur digestion in the lab 2Health News:Bonn scientists simulate dinosaur digestion in the lab 3
(Date:8/28/2015)... Aug. 28, 2015  Perrigo Company plc ("Perrigo") (NYSE: ... completed the acquisition of leading OTC brands from GSK ... The transaction is a clear demonstration of Perrigo,s unique ... European distribution network spanning 36 countries.  ... commented, "We are excited to complete this transaction, ...
(Date:8/28/2015)... Aug. 28, 2015 , Joint ... Ra from Biostar , Published in ,Stem Cells ... of lifespan through multiple IV administration of Adipose-derived MSC ... life expectancy found , Commercialization within 5 years ... the possibility that adult mesenchymal stem cells (MSCs) may ...
(Date:8/28/2015)... LONDON , August 28, 2015 ... approach seamlessly connects people, technologies and care ... improving outcomes and the cost of healthcare delivery ... AEX: PHIA) today announced its presence at  ESC Congress 2015 , ... Heart Model A.I. , EchoNavigator and IntelliSpace Cardiovascular, that connect ...
Breaking Medicine Technology:Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 2Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 3Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 4Korean Researchers Find the Possibility that Adult Mesenchymal Stem Cells (MSCs) May Extend Lifespan 2Philips Showcases New Integrated Cardiology Solutions to Advance Minimally Invasive Procedures at ESC Congress 2015 2Philips Showcases New Integrated Cardiology Solutions to Advance Minimally Invasive Procedures at ESC Congress 2015 3Philips Showcases New Integrated Cardiology Solutions to Advance Minimally Invasive Procedures at ESC Congress 2015 4
... Ridge Diagnostics, Inc., a neurodiagnostic company, announced that ... test for Major Depressive Disorder(MDD), will be presented during ... to Aid in Diagnosis, Treatment and Management of Major ... Meeting, May 20, 2009. The blood test, for the ...
... ATLANTA, May 20 /PRNewswire-FirstCall/ -- ... an Atlanta-based, publicly traded biopharmaceutical company developing human ... Virus) and other infectious agents, announced today that ... band Styx, has joined the GeoVax Labs awareness ...
Cached Medicine Technology:Ridge Diagnostics, Inc. Clinical Data on Blood Test for Depression Presented at American Psychiatric Association Annual Meeting 2Chuck Panozzo, Founder of Rock Band Styx, Joins GeoVax Labs, Inc. as an Advocate for Its HIV/AIDS Vaccine 2Chuck Panozzo, Founder of Rock Band Styx, Joins GeoVax Labs, Inc. as an Advocate for Its HIV/AIDS Vaccine 3Chuck Panozzo, Founder of Rock Band Styx, Joins GeoVax Labs, Inc. as an Advocate for Its HIV/AIDS Vaccine 4